Boan Biotech Receives Strategic Investments to Boost Global Development of Biopharmaceutical Business - Global Collaboration

Products>Global Collaboration

Boan Biotech Receives Strategic Investments to Boost Global Development of Biopharmaceutical Business

May 18,2021

As a holding subsidiary of Luye Pharma Group, Boan Biotech has received approximately RMB 877 million between Dec. 2020 and Jan. 2021 from a number of investors, bringing the company’s post-money valuation following this round of financing to RMB 5.6 billion.
The capital raised will help Boan Biotech accelerate the clinical development of its varied innovative antibody and biosimilar products, enhancing competitive strengths and facilitating rapid, stable growth.
Boan Biotech’s antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology, and ADC Technology. The company has developed more than 10 innovative antibody product candidates and 8 biosimilar products, while actively exploring cutting-edge fields such as cell therapy.

Products>Global Collaboration

Boan Biotech Receives Strategic Investments to Boost Global Development of Biopharmaceutical Business

May 18,2021

As a holding subsidiary of Luye Pharma Group, Boan Biotech has received approximately RMB 877 million between Dec. 2020 and Jan. 2021 from a number of investors, bringing the company’s post-money valuation following this round of financing to RMB 5.6 billion.
The capital raised will help Boan Biotech accelerate the clinical development of its varied innovative antibody and biosimilar products, enhancing competitive strengths and facilitating rapid, stable growth.
Boan Biotech’s antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology, and ADC Technology. The company has developed more than 10 innovative antibody product candidates and 8 biosimilar products, while actively exploring cutting-edge fields such as cell therapy.